Skip to content

Lobbying by Canadian Organization for Rare Disorders: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Canadian Organization for Rare Disorders

Meetings this Parliament
5
With MPs
3
Since Nov 2021
10
Active registrations
1

Most recent reported meeting: Jul 30, 2026.

Bills they've lobbied on

Named in their own descriptions of meetings or of their registration. Their words are quoted below each bill.

Who they meet

Since the current Parliament opened.

MPs

Institutions

  • House of Commons3
  • Health Canada (HC)2

Registrations in effect

Consultant In effect since May 21, 2026

Consultant William Dempster of 3Sixty Public Affairs Inc.

Consultant lobbyists

  • William Dempster Former public office holder

    Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)

  • William Dempster Former public office holder

    Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)

Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (10)
  • Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.
  • Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board as they relate to access for patients to rare disease medicines
  • Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.
  • Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.
  • Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
  • Scientific Research and Experimental Development Tax Incentive Program as it pertains to research and development of treatments for rare disorders.
  • Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients
  • Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders.
  • Implementation of the Pharmacare Act as it relates to rare disease medicines.
  • Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Registration 778465-240921-16. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by William Dempster · Consultant

    Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients Read more

    Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

    Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

    Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

    Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders.

    Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

    Official report

  • Reported by William Dempster · Consultant

    C-265

    Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries. Read more

    Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.

    Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

    Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients

    Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

    Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

    Official report

  • Reported by William Dempster · Consultant

    • Daniel MacDonald · Director General, Office of Pharmaceutical Management Strategies, Health Canada (HC)

    C-265

    Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases. Read more

    Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

    Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

    Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients

    Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

    Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

    Official report

  • Reported by William Dempster · Consultant

    C-265

    Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines. Read more

    Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.

    Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

    Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients

    Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders.

    Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

    Official report

  • Reported by William Dempster · Consultant

    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)

    C-265

    Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients Read more

    Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.

    Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders.

    Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

    Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

    Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

    Official report

  • Reported by William Dempster · Consultant

    • Stephanie Dunlop · Director of Stakeholder Relations and Outreach, House of Commons
    • David Murray · Director of Policy, House of Commons

    Health

    Official report

  • Reported by William Dempster · Consultant

    • Supriya Sharma · Chief Medical Advisor to the Deputy Minister & Senior Medical Advisor, Health Canada (HC)
    • Eric Bélair · Associate Assistant Deputy Minister, Health Canada (HC)
    • Celia Lourenco · Acting Associate Assistant Deputy Minister, Health Canada (HC)

    Health

    Official report

  • Reported by William Dempster · Consultant

    • Sandenga Yeba · Deputy Director of Policy, Health Canada (HC)

    Health

    Official report

  • Reported by William Dempster · Consultant

    • Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)

    HealthIndustryScience and TechnologyTaxation and Finance

    Official report

  • Reported by William Dempster · Consultant

    • David Lee · Chief Regulatory Officer, Health Canada (HC)
    • Nancy Hamzawi · Assistant Deputy Minister, Health Canada (HC)

    HealthIndustryScience and TechnologyTaxation and Finance

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.